Inflammatory bowel diseases (IBD), encompassing Crohn's disease (CD) and ulcerative
colitis (UC), are intimately associated with inflammation and overproduction of reactive …

Background: Mucosal healing (MH) was proposed to be an ideal treatment goal for patients
with inflammatory bowel disease (IBD). Instead of endoscopy to confirm MH, biomarkers are …

Diagnosis and prognosis of inflammatory bowel disease (IBD)—a chronic inflammation that
affects the gastrointestinal tract of patients—are challenging, as most clinical symptoms are …

The number of patients with inflammatory bowel disease (IBD) is increasing worldwide.
Endoscopy is the gold standard to assess the condition of IBD. The problem with this …

Precise diagnostic biomarker in inflammatory bowel diseases (IBD) is still missing. We
conducted a comprehensive overview of oxidative stress markers (OSMs) as potential …

Background & Aims Current therapies for ulcerative colitis (UC) fail to achieve satisfactory
disease control. Selective inhibition of Janus kinase (JAK) type 1 may improve clinical …

Background Mucosal healing, confirmed by endoscopic evaluation, is the long-term goal of
treatment for Crohn's disease (CD). Leucine-rich alpha-2 glycoprotein (LRG) is a new serum …

Background Bowel urgency reduces ulcerative colitis patients' quality of life. Mirikizumab, a
p19-directed anti-IL-23 antibody, demonstrates ulcerative colitis efficacy. Mirikizumab …

Introduction Crohn's disease (CD) is a complex disease, and assessing activity is
challenging due to pathobiologic process eg ECM remodeling, mucosal damage, and …

Achieving mucosal healing in patients with inflammatory bowel disease is related to a higher
incidence of sustained clinical remission and it translates to lower rates of hospitalisation …